June 18, 2026 - At the recently concluded 20^th Annual Scientific Meeting of Asia Pacific Society of Cardiovascular and Interventional Radiology (APSCVIR 2026), Chengdu New Radiomedicine Technology Co., Ltd. ("NRT") showcased its latest innovations spanning interventional radiology and nuclear medicine.

During the keynote session, Congress Chair Gaojun Teng presented several cutting-edge interventional radiology programs under development across the Asia-Pacific region and specifically mentioned the clinical progress of TareSphere^TM (Yttrium-90 Carbon Microspheres), which drew strong interests from KOLs and industry experts at the conference.

The team engaged with regional and global KOLs at NRT's booth

Dr. David Liu, Chief Medical Officer of NRT and a renowned expert in interventional radiology, was invited to chair multiple scientific sessions and deliver keynote presentations. With expertise in clinical translation of radioembolization for liver cancer and radiopharmaceutical precision medicine, Dr. Liu brings strong medical leadership to advance NRT's pipeline and strengthen international collaboration.

Chief Medical Officer Dr. David Liu contributed to the scientific programs

About TareSphere^TM

TareSphere^TM is a proprietary radioactive microsphere product developed by NRT. Leveraging NRT's well-established platform for isotopes and radiopharmaceuticals, Yttrium-90 is manufactured on-site for microsphere production. This approach reduces reliance on reactor-based production and enables a scalable and reliable supply of radiopharmaceuticals.

NRT remains dedicated to collaborating and expanding access to effective clinical solutions for patients benefit globally.